Key Stats for Abbott Stock
- 52-Week Range: $100.9 to $139.1
- Current Price: $102.9
- Street High Target: $
What Happened?
Abbott Laboratories (ABT), a diversified medical device and diagnostics company, closed its $23 billion acquisition of Exact Sciences on March 23, giving it Cologuard and Oncotype DX and a direct entry into a $60 billion U.S. cancer screening market, even as ABT trades near its 52-week low of $100.88.
Abbott financed the deal with a $20 billion senior notes offering that closed March 9, covering tranches from 3.7% notes due 2029 to 6.0% notes due 2066, while simultaneously guiding for roughly $3.0 billion in incremental Exact Sciences revenue and $0.20 adjusted EPS dilution in 2026.
Abbott’s continuous glucose monitor business, FreeStyle Libre, a wearable sensor that measures blood sugar in real time and now generates $7.6 billion annually, grew 17% in FY 2025, marking three consecutive years of more than $1 billion in annual CGM revenue gains.
Robert Ford, Chairman and CEO, stated on the Q4 2025 earnings call that “cancer diagnostics is going to be a very important clinical and medical need for society — for global society,” tying directly to Abbott’s March 30 integration of Precision Oncology test ordering into Flatiron Health’s OncoEMR platform, which reaches 1,600 community cancer care centers and 4,700 providers across North America.
Abbott’s Q1 2026 earnings release on April 16 will be the first test of post-acquisition execution, with management guiding for 10% adjusted EPS growth at the midpoint, $3.0 billion in Exact Sciences revenue, a pending FDA decision on the dual glucose-ketone sensor targeting the 5 million SGLT2 users not yet on CGM, and $6.7 billion remaining under its active share repurchase program.
Wall Street’s Take on ABT Stock
Abbott’s $23 billion Exact Sciences close on March 23 adds a $3.0 billion cancer diagnostics revenue stream and accelerates total company revenue growth to an estimated 14.2% in 2026, directly justifying the forward earnings inflection already underway.
Revenue jumps from $44.3 billion in FY 2025 to an estimated $50.6 billion in 2026, as TIKR estimates, anchored by Exact Sciences’ contribution, FreeStyle Libre CGM’s $7.6 billion base growing at low-to-mid teens, and lapping of $900 million in prior-year COVID and China VBP diagnostic headwinds.
Analysts covering ABT remain firmly constructive, with 16 buys and 6 outperforms against just 7 holds and zero sells among 25 analysts, pointing to a mean price target of $132.28 that implies 28.6% upside from the current $102.87 close on April 2.
The spread between the $113.00 analyst floor and the $158.00 ceiling reflects precisely two binary outcomes already in the story: downside anchors on Libre 3 recall litigation exposure and Nutrition recovery execution, while the upside case prices in CGM non-insulin reimbursement expansion and Exact Sciences integration outperformance.
What Does the Valuation Model Say?
TIKR’s mid-case model targets $150.64 by December 31, 2030, assuming 7.0% revenue CAGR and 6.0% EPS CAGR through 2030, driven by Exact Sciences’ cancer diagnostics ramp and FreeStyle Libre’s continued $1 billion-plus annual CGM growth increments, as TIKR estimates.
ABT currently trades at 18.8x forward normalized EPS of $5.47, a meaningful discount to its historical 22–25x range during prior high-growth cycles, even as the 2026 growth profile is structurally stronger post-Exact Sciences, making ABT stock undervalued relative to its own earnings history.
The FCF inflection makes the undervaluation undeniable: free cash flow, the actual cash a business generates after capital expenditures, rises from $7.4 billion in 2025 to an estimated $9.2 billion in 2026, as TIKR estimates, a 23.8% jump that funds both the growing dividend and the $6.7 billion buyback authorization.
CEO Robert Ford’s explicit framing of Exact Sciences as “a whole new growth vertical” tied directly to the March 30 Flatiron OncoEMR integration spanning 4,700 providers signals that commercial deployment is already moving, not queued.
The single break risk is Nutrition: Ford guided for challenged H1 performance as the business absorbs deliberate price cuts to reignite volume, and a slower-than-expected recovery would pressure the 14.2% revenue growth estimate for 2026.
Abbott’s April 16 Q1 2026 earnings release is the first post-acquisition read, and the number to watch is whether Exact Sciences contributes to the $1.12–$1.18 Q1 EPS guidance range without incremental dilution beyond the guided $0.20 full-year drag.
Should You Invest in Abbott Laboratories?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up ABT stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Abbott Laboratories alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ABT stock on TIKR for Free →
